STAM Binding Protein Regulated by Hsa_circ_0007334 Exerts Oncogenic Potential in Pancreatic Cancer
Overview
Authors
Affiliations
Background: Pancreatic cancer (PC) is a highly aggressive and metastatic malignancy. The molecular events related to PC have not yet been fully elucidated. The STAM binding protein (STAMBP), a deubiquitinase, contributes to carcinogenesis in several types of cancer. Our study aims to investigate the function of STAMBP in the progression of PC.
Methods: Fifteen pairs of tumor and tumor-adjacent tissues were obtained from PC patients. Human pancreatic cancer cell lines, SW 1990 and BxPC-3, were transfected with short hairpin RNA targeting STAMBP or/and vectors overexpressing wild-type STAMBP or STAMBP D348A mutants (inactive mutants of STAMBP). SW 1990 cells were co-transfected with vectors overexpressing STAMBP and small interfering RNA targeting hsa_circ_0007334.
Results: STAMBP was overexpressed in the tumor tissues as compared with the tumor-adjacent tissues from PC patients. Higher STAMBP expression in the tumor tissues showed worse prognosis. Loss/gain-of-function experiments revealed that STAMBP promoted the malignant behaviors of PC cells in vitro and xenograft tumor growth in vivo. Activation of NF-κB in PC cells was triggered by STAMBP. However, inactive mutants of STAMBP lost these biological functions in PC. hsa_circ_0007334, an oncogene in PC progression, was found to up-regulate STAMBP expression in PC cells. STAMBP up-regulation reversed the effects of hsa_circ_0007334 silencing on cell mobility.
Conclusions: These results indicated that STAMBP depended on its deubiquitinase activities to induce the malignant behaviors of PC cells and was involved in the regulatory mechanism of hsa_circ_0007334 on PC cell mobility. Our findings provide a novel insight into the molecular mechanism of PC.
Zhang W, Xu Z, Du Y, Liu T, Xiong Z, Hu J Cell Death Dis. 2024; 15(9):657.
PMID: 39242557 PMC: 11379802. DOI: 10.1038/s41419-024-07048-z.
CircRNAs in Pancreatic Cancer: New Tools for Target Identification and Therapeutic Intervention.
Weidle U, Nopora A Cancer Genomics Proteomics. 2024; 21(4):327-349.
PMID: 38944427 PMC: 11215428. DOI: 10.21873/cgp.20451.
Xie S, Zhang R, Tang Y, Dai Q Front Immunol. 2024; 15:1373723.
PMID: 38742115 PMC: 11089180. DOI: 10.3389/fimmu.2024.1373723.
Karihtala P, Leivonen S, Puistola U, Urpilainen E, Jaaskelainen A, Leppa S Breast Cancer Res. 2024; 26(1):61.
PMID: 38594742 PMC: 11005292. DOI: 10.1186/s13058-024-01812-x.
Liu S, Wang P, Ye L, Liu C, Xiao W, Gao C Acta Biochim Biophys Sin (Shanghai). 2023; 55(8):1327-1330.
PMID: 37337635 PMC: 10448038. DOI: 10.3724/abbs.2023102.